focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Europe down after Easter holiday weekend

Tue, 02nd Apr 2024 16:57

(Alliance News) - The FTSE 100 took a hit on Tuesday, after a boost from London's miners and oil firms were not enough to lift the index.

The FTSE 100 index closed down 17.53 points, 0.2%, at 7,935.09. The FTSE 250 ended down 170.84 points, 0.9%, at 19,713.89, and the AIM All-Share closed down 0.86 of a point, 0.1%, at 742.40.

The Cboe UK 100 ended down 0.3% at 793.40, the Cboe UK 250 closed down 1.1% at 17,147.56, and the Cboe Small Companies ended down slightly at 14,553.13.

In European equities on Tuesday, the CAC 40 in Paris ended down 0.9%, while the DAX 40 in Frankfurt ended down 1.1%.

After a long Easter weekend, markets reopened on Tuesday to a busy day on the corporate and economic calendar.

Data from S&P Global on Tuesday showed the UK manufacturing sector crossing the no-change mark into growth territory in March.

The seasonally adjusted S&P Global UK manufacturing purchasing managers' index reading was 50.3 points in March, up from 47.5 in February and beating the earlier flash estimate of 49.9.

The latest figure was above the 50-point no-change mark, meaning the UK manufacturing sector returned to growth territory.

PMI data from the eurozone was more disheartening, however.

The latest Hamburg Commercial Bank manufacturing PMI fell to 46.1 points in March, from 46.5 in February. The latest reading was a three-month low, but topped the flash estimate of 45.7 points.

Hamburg Commercial Bank analyst Cyrus de la Rubia commented: "It's a bit disheartening: over the last eight months, the manufacturing industry has been gradually climbing the output PMI ladder, but it still finds itself on the basement staircase."

More positively for the eurozone, Germany saw inflation ease in March.

The consumer price index rose by 2.2% annually in March, ebbing from a 2.5% rise in February. This came in line with FXStreet-cited market consensus and is the lowest value since April 2021.

Analysts at ING said: "despite the early timing of Easter this year, prices for leisure, packaged holidays and hotels and restaurants rose less than expected month-on-month than expected. The Easter bunny effect, ie the base effect stemming from the timing of Easter, was hardly visible this year."

The pound was quoted at USD1.2564 at the London equities close Tuesday, lower compared to USD1.2640 at the close on Thursday. The euro stood at USD1.0771 at the European equities close Tuesday, down against USD1.0803 at the same time on Thursday. Against the yen, the dollar was trading at JPY151.60, up compared to JPY151.29 late Thursday.

In the FTSE 100, miners were among the better large-cap performers. Fresnillo, Anglo American, Glencore, and Rio Tinto traded 7.6%, 4.6%, 3.0%, and 2.0% higher respectively.

The miners got a boost from the latest set of PMI data from China. Monthly factory activity in China grew for the first time in half a year, official figures showed, in a positive sign for policymakers seeking to revive the world's second-largest economy.

The PMI came in at 50.8 points in March, according to the National Bureau of Statistics, up from 49.1 in February. The last expansion in China's monthly PMI was in September, with factory activity consistently negative since then, according to NBS data.

The trend of improvement was confirmed by the Caixin manufacturing PMI, which edged up to 51.1 from 50.9.

Oil firms also did well on Tuesday, on the back of higher oil prices. Shell and BP rose 3.2% and 2.5% respectively.

Brent oil was quoted at USD88.11 a barrel at the London equities close Tuesday, up from USD86.56 late Thursday.

"The ongoing rise in oil prices amid a tighter supply outlook is a worry for corporates and consumers as it is a major inflationary force," said Russ Mould, investment director at AJ Bell.

On the other hand, housebuilders were in the red. Taylor Wimpey, Persimmon, and Barratt Developments lost 3.1%, 3.5%, and 0.1%, respectively.

They were hit by a fall in house prices in the most recent month.

The Nationwide house price index showed a 0.2% decline in seasonally adjusted UK house prices in March from February, compared to a 0.7% rise in February from January. According to FXStreet, market consensus expected the house price index to rise 0.3% last month.

Annually, the house price index rose 1.6% in March compared to a year ago, improving from an annual rise of 1.2% in February, but undershooting FXStreet-cited expectations of a 2.4% rise.

Elsewhere in London, on AIM, Orcadian Energy surged 86%.

The oil and gas development company said it has completed the farm-out of 81% interest in Licence P2244, which contains the Pilot field, to Ping Petroleum UK PLC. Ping is focused on shallow water offshore production, and has a significant acreage holding to the East of Pilot.

On the other hand, Redx Pharma plummeted 65%, after it said it intends to cancel its shares from trading on AIM in London.

The clinical-stage biotechnology company said the board unanimously concluded that it is in the best interests of the company to re-register as a private limited company, as it is "still liquidity constrained" on AIM.

Chair Jane Griffith said: "The board believes that as a private company we can access a broader universe of specialty investors and, accordingly, a larger quantum of future funding required to execute our strategy and maximise our value in the interests of all our shareholders."

Stocks in New York were lower at the London equities close, with the DJIA down 1.1%, the S&P 500 index down 0.9%, and the Nasdaq Composite down 1.2%.

Gold was quoted at USD2,266.55 an ounce at the London equities close Tuesday, up against USD2,221.01 at the close on Thursday.

In Wednesday's UK corporate calendar, there are full year results from Hilton Food, Impax Environmental Markets, and Pantheon Infrastructure.

The economic calendar for Wednesday has unemployment and CPI data from the eurozone out at 1000 BST.

There are also a number of Federal Reserve members who are scheduled to speak, including Fed Chair Jerome Powell, Vice Chair Michale Barr, Governor Michelle Bowman, and Governor Adriana Kugler.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
17 May 2023 14:44

Redx Pharma half-year loss doubles amid costs of failed Jounce merger

(Alliance News) - Redx Pharma PLC on Wednesday said its half-year loss nearly doubled, due to lower revenue and higher expenses, but it noted progress in therapeutics trials and said it "retains the foundations for longer term success".

Read more
11 May 2023 18:17

IN BRIEF: Redx reports positive preclinical data for fibrosis drug

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company - Announces preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor 1/2 discovery programme, as presented yesterday at the Resistant Tumour Microenvironment, Keystone Symposia, in Vancouver. Notes the data presented were from preclinical models of pancreatic ductal adenocarcinoma and triple negative breast cancer in combination with chemotherapy and immunotherapy, as current standard of care. Says RXC007, in combination with gemcitabine/Abraxane in metastatic and high-extra cellular matrix patient-derived PDAC models, was shown to increase survival compared to single agent standard of care alone. The combination of RXC007 with standard of care provided a significant increase in median survival days from date of treatment in a dose dependent manner. These new data on RXC007 complement those also presented at the meeting by collaboration partner the Garvan Institute of Medical Research on REDX10616, a close analogue of RXC007. Taken together, these data provide a strong rationale for the potential of ROCK2 inhibition in combination with standard of care as a potential treatment for cancer-associated fibrosis. Redx plans to further investigate this treatment setting with the company's next-generation ROCK2 inhibitor, RXC007. Further, at the Keystone Symposia, data were also presented from Redx's DDR1/2 programme in combination with anti-PD-1 in TNBC models. Using a tool DDR1/2 inhibitor, in combination with anti-PD-1, in the TNBC E0771 model resulted in a statistically significant increase in survival when compared to the control group, an effect not observed with either single agent alone.

Read more
10 May 2023 15:45

UK earnings, trading statements calendar - next 7 days

Thursday 11 May 
3i Group PLCFull Year Results
Airtel Africa PLCFull Year Results
Eurocell PLCTrading Statement
Donegal Investment Group PLCHalf Year Results
Grainger PLCHalf Year Results
Hurricane Energy PLCFull Year Results
ICG Enterprise Trust PLCFull Year Results
IQE PLCFull Year Results
ITV PLCTrading Statement
John Wood Group PLCTrading Statement
Morgan Advanced Materials PLCTrading Statement
Rolls-Royce Holdings PLCTrading Statement
S4 Capital PLCQ1 Results
TBC Bank Group PLCQ1 Results
Friday 12 May 
Allianz Technology Trust PLCQ1 Results
Balfour Beatty PLCTrading Statement
Beazley PLCQ1 Results
CMO Group PLCFull Year Results
Monday 15 May 
CentralNic Group PLCFull Year Results
Cerillion PLCHalf Year Results
Currys PLCTrading Statement
Diploma PLCHalf Year Results
Equals Group PLCTrading Statement
Finsbury Growth & Income Trust PLCHalf Year Results
Instem PLCFull Year Results
JPMorgan Multi-Asset Growth & Income PLCFull Year Results
Westminster Group PLCFull Year Results
Tuesday 16 May 
Angling Direct PLCFull Year Results
boohoo Group PLCFull Year Results
Britvic PLCHalf Year Results
Burford Capital LtdFull Year Results
Cornerstone FS PLCFull Year Results
DCC PLCFull Year Results
Essentra PLCTrading Statement
Greggs PLCTrading Statement
Hyve Group PLCHalf Year Results
Imperial Brands PLCHalf Year Results
Land Securities Group PLCFull Year Results
Likewise Group PLCFull Year Results
Marston's PLCHalf Year Results
Renew Holdings PLCHalf Year Results
Smartspace Software PLCFull Year Results
Vodafone Group PLCFull Year Results
Zytronic PLCHalf Year Results
Wednesday 17 May 
Auction Technology Group PLCHalf Year Results
Bank of Georgia Group PLCQ1 Results
British Land Co PLCFull Year Results
Experian PLCFull Year Results
JD Sports Fashion PLCFull Year Results
Keller Group PLCTrading Statement
Ninety One PLC and LtdFull Year Results
Redx Pharma PLCHalf Year Results
Sage Group PLCHalf Year Results
Scottish Mortgage Investment Trust PLCFull Year Results
TP ICAP Group PLCQ1 Results
Watches of Switzerland Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2023 18:05

TRADING UPDATES: Redx confirms Jounce deal lapses, Tirupati seals deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
27 Mar 2023 14:34

Redx Pharma's bid to buy Jounce snubbed by Concentra's higher offer

(Alliance News) - Redx Pharma PLC on Monday noted that Jounce Therapeutics Inc, which it was close to buying, was bought by Concentra Biosciences LLC for a higher price.

Read more
27 Mar 2023 14:16

Jounce agrees Concentra Bioscences takeover, ditches Redx Pharma

(Sharecast News) - Jounce Therapeutics said on Monday that it was ditching a planned merger with AIM-listed Redx Pharma, opting instead to be bought by Concentra Bioscences.

Read more
8 Mar 2023 12:07

LONDON MARKET MIDDAY: Stocks down, pound below USD1.19 on US rate view

(Alliance News) - Stock prices in London were lower at midday on Wednesday, with investors still reeling from surprisingly hawkish comments by US Federal Reserve Chair Jerome Powell on Tuesday.

Read more
8 Mar 2023 11:52

Redx Pharma shares slide on RXC004 monotherapy blow

(Alliance News) - Redx Pharma PLC on Wednesday said first results of its phase 2 programme indicate were not sufficient enough to support the development of its RXC004 treatment as a monotherapy.

Read more
8 Mar 2023 10:42

AIM WINNERS & LOSERS: Redx drops on disappointing cancer drug results

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
7 Mar 2023 15:44

UK shareholder meetings calendar - next 7 days

Wednesday 8 March 
Amigo Holdings PLCGM re the company's capital position
boohoo Group PLCGM re adoption of the Growth Plan
Creo Medical Group PLCGM re open offer shares
Globalworth Real Estate Investments LtdEGM re grant options and script dividends
Henderson Opportunities Trust PLCAGM
Jersey Electricity PLCAGM
Thursday 9 March 
CT Capital & Income Investment Trust PLCAGM
Shoe Zone PLCAGM
WAG Payment Solutions PLCGM re proposed acquisition of Inelo
Friday 10 March 
Atrato Onsite Energy PLCAGM
Malin Corp PLCAGM
Mineral & Financial Investments LtdAGM
Monday 13 March 
BlackRock Energy & Resources Income Trust PLCAGM
Hercules Site Services PLCAGM
Hummingbird Resources PLCGM re strategic investment and placement
Ironveld PLCGM re second placing shares on AIM
Tuesday 14 March 
Georgia Capital PLCGM re company's transfer from Premium to Standard listing
MTI Wireless Edge LtdAGM
Redx Pharma PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
23 Feb 2023 10:24

Redx Pharma and Jounce Therapeutics agree transatlantic merger

(Alliance News) - Redx Pharma PLC and Jounce Therapeutics Inc on Thursday said they have agreed to an all-share merger that will create a USD425 million company focused on the treatment of cancer and fibrotic diseases.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more
9 Feb 2023 12:25

IN BRIEF: Redx Pharma makes progress on fibrosis candidate study

Redx Pharma PLC - Alderley Edge, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Updates on its lead fibrosis candidate, RXC007, which is currently being assessed in a phase 2a study. Says regulatory and ethics approvals for the 28-day and 12-week cohorts of the study have been received in five countries. Adds recruitment is progressing at a number of study sites, but says enrolment in the US 12-week cohort has not begun due to a partial US Food & Drug Adminstration hold, pending a data readout from an ongoing non-clinical programme. The requested data is expected later this year. US enrolment in the 28-day cohort is unaffected.

Read more
20 Dec 2022 14:29

EARNINGS SUMMARY: Goodwin achieves rise in interim profit and revenue

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
16 Dec 2022 21:22

TRADING UPDATES: Uniphar takeover fails; Pearson notes redemption end

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.